Freeline Presents Data Highlighting Platform Technology at the American Society of Gene and Cell Therapy Annual Meeting 2021
11 mai 2021 07h00 HE
|
Freeline Therapeutics
LONDON, May 11, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021
27 avr. 2021 16h31 HE
|
Freeline Therapeutics
LONDON, April 27, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline to Participate in Upcoming Investor Conferences in April and May 2021
21 avr. 2021 16h01 HE
|
Freeline Therapeutics
LONDON, April 21, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Reports Full Year 2020 Financial Results and Business Highlights
31 mars 2021 16h02 HE
|
Freeline Therapeutics
Plans to have three AAV gene therapy programs in the clinic by year-end 2021 Data from FLT180a Phase 1/2 trial for Hemophilia B demonstrated potential for durable normalization of Factor IX...
Freeline to Present at Upcoming Investor Conferences
30 mars 2021 16h01 HE
|
Freeline Therapeutics
LONDON, March 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline Appoints Colin Love, PhD to Board of Directors
11 mars 2021 07h00 HE
|
Freeline Therapeutics
LONDON, March 11, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline to Present at Upcoming Investor Conferences
02 mars 2021 07h00 HE
|
Freeline Therapeutics
LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene...
Freeline Announces Expansion of Executive Leadership
16 févr. 2021 07h00 HE
|
Freeline Therapeutics
Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments Chief Financial Officer Brian M. Silver leaving...
Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium™
08 févr. 2021 16h01 HE
|
Freeline Therapeutics
Data demonstrate potential of FLT201 to deliver sustained levels of β-glucocerebrosidase (GCase) variant 85, a proprietary engineered GCase that penetrates target tissues in Gaucher disease ...
Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program
08 févr. 2021 07h00 HE
|
Freeline Therapeutics
Targeting initiation of dose confirmation trial by end of 2021 with data readout by end of 2022 Initiation of Phase 3 pivotal trial targeted by mid-2023, with data readout and BLA filing targeted by...